Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

Prior treatment

• Patients who have undergone a kidney transplant;

Other illness

• Systemic diseases that may cause mesangial IgA deposition.
• Patients with presence of other glomerulopathies and/or nephrotic syndrome
• Patients with acute, chronic, or latent infectious disease including hepatitis, tuberculosis (TB), human immunodeficiency virus (HIV), and chronic urinary tract infections;
• Patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled
• Patients with history of unstable angina, class III or IV congestive heart failure, and/or clinically significant arrhythmia, as judged by the Investigator;
• Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator.
• Patients with diagnosed malignancy within the past 5 years.

Other

• Patients with liver cirrhosis, as assessed by the Investigator;

• Patients that completed study Nef-301
• On a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or maximum tolerated dose according to the 2012 KDIGO guidelines
• Willing and able to provide written informed consent.
• UPCR equal to or more than 0.8 g/gram
• eGFR equal to or more than 30 mL/min per 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.